| Autor: |
Gong S; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.; Department of Microbiology, Immunology & Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.; Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78227, USA., Gautam S; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.; Department of Biology, University of Louisiana at Lafayette, Lafayette, LA 70503, USA., Coneglio JD; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA., Scinto HB; Department of Microbiology, Immunology & Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.; Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78227, USA., Ruprecht RM; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.; Department of Microbiology, Immunology & Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.; Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.; Department of Biology, University of Louisiana at Lafayette, Lafayette, LA 70503, USA. |
| Abstrakt: |
When constructing isogenic recombinant IgM-IgG pairs, we discovered that μ heavy chains strongly prefer partnering with λ light chains for optimal IgM expression in transiently cotransfected Expi293 cells. When μ chains were paired with κ light chains, IgM yields were low but increased by logs-up to 20,000 X-by using λ chains instead. Switching light chains did not alter epitope specificity. For dimeric IgA2, optimal expression involved pairing with λ chains, whereas light-chain preference varied for other immunoglobulin classes. In summary, recombinant IgM production can be drastically increased by using λ chains, an important finding in the use of IgM for mucosal immunoprophylaxis. |
